Mnemosyne Pharmaceuticals Secures $6,000,000 Series A Funding

Feed Type
Link
http://www.venturedeal.com/Search/SearchResultTransactionDetail.aspx?TransactionId=8dacf0a1-082a-41bb-aac5-9c9fbac7b951&Preview=1
Date
6/21/2013
Company Name
Mnemosyne Pharmaceuticals
Mailing Address
One Davol Square Providence, RI 02903
Company Description
The company is a Providence-based drug discovery venture aiming to develop small molecule therapeutics to treat schizophrenia and other cognitive and neuropsychiatric disorders.
Website
http://www.mnemosynepharma.com
Transaction Type
Venture Equity
Transaction Amount
$6,000,000
Transaction Round
Series A
Proceeds Purposes
Undisclosed
M&A Terms
Venture Investor
Atlas Venture
Venture Investor
Clal Biotechnology Industries Ltd.